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Abstract
Background: Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
(MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies
(mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and
its therapeutic utility was investigated.
Methodology and Principal Findings: A chimeric rabbit/human Fab library was generated from immunized rabbits and
selected by phage display. Chimeric rabbit/human Fab and IgG1 were investigated for their capability to bind to human and
mouse ROR1, to mediate antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and
internalization, and to agonize or antagonize apoptosis using primary CLL cells from untreated patients as well as MCL cell
lines. A panel of mAbs demonstrated high affinity and specificity for a diverse set of epitopes that involve all three
extracellular domains of ROR1, are accessible on the cell surface, and mediate internalization. The mAb with the highest
affinity and slowest rate of internalization was found to be the only mAb that mediated significant, albeit weak, ADCC. None
of the mAbs mediated CDC. Alone, they did not enhance or inhibit apoptosis.
Conclusions and Significance: Owing to its relatively low cell surface density, ROR1 may be a preferred target for armed
rather than naked mAbs. Provided is a panel of fully sequenced and thoroughly characterized anti-ROR1 mAbs suitable for
conversion to antibody-drug conjugates, immunotoxins, chimeric antigen receptors, and other armed mAb entities for
preclinical and clinical studies.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
presence of a monoclonal B-cell population with a count of
.5,000 cells/mL in the peripheral blood [1,2]. In the United
States of America, CLL is the most common leukemia with
roughly 15,000 new cases and 5,000 deaths per year. Whereas
approximately half of CLL patients have an indolent clinical
course that does not require treatment for many years, a more
aggressive clinical course that necessitates treatment within a few
years is diagnosed for the other half. These differences in clinical
course correlate with molecular markers, including the mutational
status of the surface immunoglobulins and the expression of
intracellular tyrosine kinase ZAP-70. Despite a typically lower
expression of CD20 compared to normal B cells, the combination
of fludarabine and cyclophosphamide (FC) with the chimeric
mouse/human anti-CD20 IgG1 monoclonal antibody (mAb)
rituximab (FCR) [3] has become standard first-line treatment that
was approved by the Food and Drug Administration (FDA) in
2010. In addition, alemtuzumab, a humanized anti-CD52 IgG1
mAb, was FDA-approved in 2001 as single agent for CLL therapy.
Alemtuzumab is frequently used for second-line treatment, but is
ineffective in CLL patients with bulky lymphadenopathy. In 2009,
fully human IgG1 mAb ofatumumab, which binds to a CD20
epitope different from rituximab, was FDA-approved for treating
CLL patients refractory to fludarabine and alemtuzumab.
With three mAbs approved for CLL out of a current total of
eleven mAbs approved for cancer therapy [4], CLL clearly has
become a preferred indication for mAbs [5]. Biologically, this can
be explained by the accessibility of leukemia cells in circulation
and the availability of effector cells and proteins that mediate
antibody-directed cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC), respectively. In addition, the only
potentially curative treatment available for CLL patients is
allogeneic hematopoietic stem cell transplantation which may
involve an endogenous antibody response against CLL cell surface
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increase progression-free survival and overall survival of CLL
patients, immune suppression caused by the expression of these
cell surface antigens on normal B cells and other leukocytes can
trigger serious infectious complications such as hepatitis B virus
reactivation and progressive multifocal leukoencephalopathy
following rituximab [7] and cytomegalovirus reactivation and
pneumocystis pneumonia following alemtuzumab [8] treatments.
These adverse events provide a rationale for the discovery of cell
surface antigens with restricted expression on CLL cells and for
the development of mAbs that selectively target them. It is
anticipated that such mAbs would facilitate a precise intervention
without concomitant immune suppression.
Mantle cell lymphoma (MCL) [9] is an incurable subtype of
non-Hodgkin lymphoma with roughly 4,000 new cases and 2,000
deaths per year in the United States of America and a median
survival of only 3–5 years. Approximately 25% of MCL patients
have a leukemic component. Interestingly, MCL and CLL cells
share the general immunophenotype CD5+ CD19+ CD20+ IgD+
IgM+ which is not found in other B-cell malignancies; however,
MCL cells are generally CD232 whereas CLL cells are CD23+.
In contrast to CLL, a common genetic abnormality characterizes
MCL. Chromosomal translocation t(11;14) places the cyclin D1
gene under the control of the immunoglobulin heavy chain
promoter, promoting entry into the cell cycle. MAb therapy is not
well established for MCL [10]. Whereas the addition of rituximab
to chemotherapy, such as CHOP (cyclophosphamide/doxorubi-
cin/vincristine/prednisone), has become standard first-line treat-
ment for non-Hodgkin lymphoma with significant benefit
compared to chemotherapy alone in follicular lymphoma and
diffuse large B cell lymphoma, only very modest benefits were
found for MCL [11]. Although radioimmunotherapy with the
FDA-approved mAbs
90Y-labeled ibritumomab tiuxetan and
131I-
labeled tositumomab, which like rituximab recognize CD20,
appears more promising [12], there clearly is a need for innovative
drug and target discovery for mAb therapy of MCL.
A candidate cell surface antigen for selective targeting of both
CLL and MCL is the receptor tyrosine kinase ROR1. The
upregulation of ROR1 mRNA in CLL was discovered by gene
expression profiling [13,14]. ROR1 and the only other member of
the ROR family, ROR2, are type I membrane proteins that share
58% amino acid sequence identity and a unique extracellular
region with one immunoglobulin (Ig), one frizzled (Fz), and one
kringle (Kr) domain followed by a transmembrane region and an
intracellular region that includes a tyrosine kinase domain [15,16].
Studies in rodents revealed that ROR1 and ROR2 are broadly
expressed in developing organs during embryogenesis and tightly
downregulated after birth [15,17,18]. Functionally, there is
growing evidence that ROR1 and ROR2 mediate noncanonical
Wnt signaling by serving as receptors for the ligand WNT5A [19].
Due to their recently discovered upregulation in certain hemato-
logic and solid malignancies [19], ROR1 and ROR2 may be
considered oncofetal proteins. We and others have shown the
restricted, uniform, and constitutive cell surface expression of
ROR1 in CLL [20,21,22]. Cell surface expression of ROR1 was
also demonstrated in both primary MCL cells and MCL cell lines
[23]. At a density of 10
3 to 10
4 molecules per cell, ROR1 revealed
selective expression on the CLL cell surface independent of the
noted molecular correlates that predict the clinical course. Normal
B cells, other normal blood cells, and normal adult tissues did not
express ROR1 at detectable levels. A portion of ROR1 was
internalized when bound by polyclonal antibodies (pAbs), and only
low concentrations of soluble ROR1 were detected in sera from
CLL patients [20]. Collectively, these findings suggested that
ROR1 would be an excellent target for mAbs and other antibody
derivatives. Given the relatively large extracellular region of
ROR1 and its organization into three independent domains, it will
be critical to identify epitopes that are suitable for mediating
ADCC, CDC, internalization, and potential functional interfer-
ence.
We previously established the generation of chimeric rabbit/
human Fab libraries and their selection by phage display as a
robust method for the generation of panels of mAbs that bind with
high specificity and affinity to different epitopes of a variety of
antigens [24,25,26,27,28]. Here we use this method to select a
panel of Fab with rabbit variable domains and human constant
domains to different epitopes in all three extracellular domains of
human ROR1. As chimeric rabbit/human Fab can be converted
to chimeric rabbit/human IgG1 with fully human Fc domains, this
strategy readily provides reagents suitable for ADCC and CDC
studies with primary human target and effector cells. Moreover,
although various humanization strategies are readily available for
rabbit variable domains [24,29,30], chimeric rabbit/human IgG1
may already be suitable for clinical studies without further
antibody engineering.
Results
Selection of chimeric rabbit/human Fab by phage display
The three extracellular domains of human ROR1 were
expressed alone (hROR1ECD) or as fusion protein with the Fc
domain of human IgG1 (Fc-hROR1) (Fig. 1). Purified Fc-hROR1
and hROR1ECD were used to immunize and boost two groups of
rabbits of the b9 allotype which we previously had shown to be
superior for the generation and selection of chimeric rabbit/
human Fab libraries [25]. RNA from spleens and bone marrow of
the two groups of rabbits, which differed with respect to
immunogen and adjuvant, were used to generate two independent
chimeric rabbit/human Fab libraries and select them by phage
display on immobilized hROR1ECD and Fc-hROR1 as described
[28]. As summarized in Table 1, seven different chimeric rabbit/
human Fab clones that bound to hROR1ECD were identified.
Among these, three clones also bound to Fc-hROR1 and cell
surface human ROR1 expressed by stably transfected human
embryonic kidney (HEK) 293F cells [31]. These three clones
(designated R11, R12, and Y31) were therefore pursued further.
The diverse amino acid sequences of both frameworks and
complementarity determining regions of the rabbit variable
domains of R11, R12, and Y31 (Fig. 2) revealed the usage of
unrelated Vk (R11, Y31), Vl (R12), and VH germlines, suggesting
the recognition of different epitopes on human ROR1.
Specificity and epitope mapping of chimeric rabbit/
human Fab and IgG1
Both chimeric rabbit/human Fab and chimeric rabbit/human
IgG1 formats were used for further characterizing the three
selected mAbs in terms of specificity and affinity. The specificity of
purified Fab and IgG1 was probed by ELISA with an extended
panel of recombinant ROR1 proteins that included Fc-hROR1,
its mouse analogue Fc-mROR1, and five Fc fusion proteins with
just one or two extracellular domains of human ROR1 (Fig. 1).
Also included was commercially available hROR2-Fc. Chimeric
rabbit/human Fab and IgG1 P14 against NgR2 [27] was used as
negative control. Fab (data not shown) and IgG1 (Fig. 3) revealed
identical binding patterns. As shown in Fig. 3A, IgG1 R11, R12,
and Y31 bound to human ROR1, but not to human ROR2. In
addition, IgG1 R11 and Y31 were found to be cross-reactive with
mouse ROR1. The binding of IgG1 R11, R12, and Y31 to just
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confirmed the recognition of three different epitopes. In selectively
recognizing Fc-hROR1kr and Fc-hROR1fz+kr, IgG1 R11 was
the only mAb that mapped to a single domain. By contrast, IgG1
R12 and Y31 selectively recognized Fc-hROR1ig+fz and Fc-
ROR1fz+kr, respectively, but not any of the single domains,
suggesting that the epitopes of these mAbs are located in the
region that links two neighboring domains, i.e. at the conjunction
of Ig and Fz domains in case of R12 and at the conjunction of Fz
and Kr domains in case of Y31. Alternatively, they may bind to
conformational epitopes that require the presence of these two
neighboring domains. Importantly, the three epitopes of IgG1
R11, R12, and Y31 were found to cover a large portion of the
extracellular region of human ROR1, allowing us to investigate
the therapeutic implications of membrane distal and proximal
binding of anti-ROR1 mAbs. The independence of the three
epitopes was also analyzed by surface plasmon resonance using a
Biacore 6100 instrument. For this, Fc-hROR1 was immobilized
on the sensor chip and IgG1 R11, R12, and Y31 were injected in
different order. As shown in Fig. 4, IgG1 R11 and R12 were
found to bind simultaneously and independently to Fc-hROR1
regardless of the sequence of injection. By contrast, IgG1 R11, but
not IgG1 R12, was found to block the binding of IgG1 Y31 when
injected first or compete with the binding of IgG1 Y31 when
injected second. Using Fab instead of IgG1 in this study gave the
same qualitative data (data not shown). Collectively, these findings
suggested that the epitopes of R11 in the Kr domain and Y31 at
the conjunction of Fz and Kr domains partially overlap whereas
R12 binds to an independent epitope at the conjunction of Ig and
Fz domains. The simultaneous binding of IgG1 R11 and R12 to
Fc-hROR1 encouraged an investigation of their therapeutic
potential in combination. A mixture of two anti-EGFR mAbs
directed against independent epitopes was recently shown to
convey superior activity in preclinical studies when compared to
either antibody alone [32].
Affinity and avidity of chimeric rabbit/human Fab and
IgG1
Surface plasmon resonance was also used to measure the affinity
and avidity of the three selected mAbs in Fab and IgG1 formats,
Figure 1. Recombinant ROR1 proteins. Eight recombinant proteins with different compositions of the three extracellular domains of ROR1 were
constructed for this study and expressed in HEK 293F cells. ROR1 Ig, Fz, and Kr domains are shown as oval, triangle, and circle, respectively (gray).
Seven recombinant proteins, including two that included all three extracellular domains of human (h) and mouse (m) ROR1 as well as five with just
one or two extracellular domains of human ROR1, were generated as C-terminal fusion to the dimeric Fc domain of human IgG1 (white) and purified
by Protein A affinity chromatography. Another recombinant protein composed of the three extracellular domains of human ROR1 alone (hROR1ECD)
was purified by ion exchange and gel filtration chromatography.
doi:10.1371/journal.pone.0021018.g001
Table 1. Panel of chimeric rabbit/human Fab selected by phage display.
Clone
1 Library Panning rounds Repeated clones Binding
hROR1ECD Fc-hROR1 hROR1ECD
2 Fc-hROR1
2 HEK 293F/hROR1
3
R11 R 4 0 26/31 ++ ++ +
R12 R 4 0 1/31 ++ ++ ++
Y4 Y 4 0 2/31 ++ 22
Y13 Y 4 0 14/31 ++ 22
Y14 Y 4 0 2/31 + 22
Y27 Y 4 0 13/31 ++ 22
Y31 Y 3 1 4/4 ++ +
1Defined by unique DNA fingerprint and sequence.
2As measured by ELISA.
3As measured by flow cytometry.
doi:10.1371/journal.pone.0021018.t001
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strongest binder with an affinity of 0.56 nM to Fc-hROR1. Fab
R11 and Y31 revealed affinities of 2.7 and 8.8 nM, respectively.
These differences were largely due to an approximately twenty
fold slower dissociation rate of Fab R12 which, in case of Fab R11,
was partially compensated by a faster association rate. Conversion
from monovalent Fab to bivalent IgG1 increased the virtual
affinity of R11, R12, and Y31 by factor 14, 5, and 12, respectively;
all three IgG1 revealed subnanomolar avidity. Confirming the
ELISA data, R11 and Y31 revealed comparable affinities and
avidities for Fc-hROR1 and Fc-mROR1, suggesting that their
epitopes are entirely conserved between human and mouse
ROR1. By contrast, R12 did not reveal detectable binding to
Fc-mROR1.
Cell surface binding of chimeric rabbit/human IgG1
As mentioned before, Fab R11, R12, and Y31 recognized cell
surface human ROR1 expressed by stably transfected HEK 293F
cells (Table 1). Using flow cytometry, we validated the selective
binding of IgG1 R11, R12, and Y31 to human MCL cell lines
JeKo-1 and HBL-2 (Fig. 6A). Human anti-tetanus toxoid mAb
TT11 in IgG1 format [31] was used as negative control. IgG1 R12
demonstrated strong and homogeneous (narrow peak) binding at
concentrations as low as 0.01 mg/mL (67 pM) (data not shown),
confirming its subnanomolar avidity found by surface plasmon
resonance. By contrast, the binding of IgG1 R11 and, in
particular, Y31 was somewhat weaker and more heterogeneous
(broader peak). Although this pattern correlates with the different
avidities found for the three mAbs (Table 2), we attribute it to the
accessibility of the three different epitopes on cell surface ROR1.
The presumed membrane distal epitope of R12 at the conjunction
of Ig and Fz domains may facilitate better access for the bulky
IgG1 format than the presumed membrane proximal epitope of
R11 and Y31 in the Kr domain and at the conjunction of Fz and
Kr domains, respectively. In fact, conversion of R11 to the less
bulky scFv-Fc format (,110 kDa; two polypeptide chains)
demonstrated significantly stronger binding at lower concentra-
tions compared to the IgG1 format (,150 kDa; four polypeptide
chains) (data not shown). An obstructed accessibility of their
epitopes may dictate a predominantly monovalent rather than
bivalent binding of IgG1 R11 and Y31 to cell surface ROR1,
offsetting their subnanomolar avidity. We next analyzed the
Figure 3. Specificity and epitope mapping studies by ELISA. (A) The binding of chimeric rabbit/human IgG1 R11, R12, Y31, and P14 to
immobilized human ROR1 (Fc-hROR1), mouse ROR1 (Fc-mROR1), and human ROR2 (hROR2-Fc) was analyzed by ELISA using goat anti-human kappa
pAbs conjugated to HRP. The binding of goat anti-human ROR2 pAbs (gahROR2) was detected with donkey anti-goat IgG (H+L) pAbs conjugated to
HRP. (B) Using the same procedure, the epitopes of IgG1 R11, R12, and Y31 were mapped with five immobilized Fc fusion proteins that consisted of
just one or two extracellular domains of human ROR1 (see Fig. 1). These were Fc-hROR1ig (ig), Fc-hROR1fz (fz), Fc-hROR1kr (kr), Fc-hROR1ig+fz
(ig+fz), and Fc-hROR1fz+kr (fz+kr). Columns indicate mean values and error bars indicate standard deviation values of side-by-side triplicates.
doi:10.1371/journal.pone.0021018.g003
Figure 2. Amino acid sequences of R11, R12, and Y31. The amino acid sequence alignment of the rabbit variable domains (Vk,V l, and VH)o f
chimeric rabbit/human Fab clones R11, R12, and Y31 is shown with framework regions (FR) and complementarity determining regions (CDR) using
Kabat numbering [46].
doi:10.1371/journal.pone.0021018.g002
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mononuclear cells (PBMC) prepared from CLL patients. Repre-
sentative flow cytometry plots from one CLL patient are shown in
Fig. 6B and corresponding mean fluorescence intensity (MFI)
values over a concentration range of 0.01 to 10 mg/mL are shown
in Table 3. Consistent with our previous study that was based on
goat anti-human ROR1 pAbs [20], IgG1 R11, R12, and Y31
selectively bound to CLL cells (CD19+ CD5+), but not to normal
T cells (CD192 CD5+) or other normal leukocytes. This finding
underscored the specificity of IgG1 R11, R12, and Y31 for human
ROR1. The pattern of binding to primary CLL cells was similar to
that noted for the JeKo-1 and HBL-2 cell lines; strong and
homogeneous binding of IgG1 R12, weaker and more heteroge-
neous binding of IgG1 R11 and Y31. Chimeric rabbit/human
IgG1 P14 against NgR2 served as negative control and did not
reveal cell surface binding to primary CLL cells (Fig. 6B). Flow
cytometry plots that show the binding of IgG1 R12 to PBMC
prepared from additional four CLL patients are shown in Fig. 7.
Gating for normal NK cells, T cells, and B cells in these CLL
patients further confirmed the specificity of IgG1 R12 for CLL
cells.
CDC assays with chimeric rabbit/human IgG1
Following confirmation of cell surface binding, we next
investigated whether our chimeric rabbit/human IgG1 can kill
cells expressing human ROR1 through complement fixation or
CDC. As target cells we used human MCL cell lines JeKo-1 and
HBL-2 in addition to PBMC prepared from CLL patients. Target
Figure 4. Epitope mapping studies by surface plasmon resonance. Shown are Biacore 6100 sensorgrams obtained for the binding of IgG1
R11, R12, and Y31 to immobilized Fc-hROR1. IgG1 were injected in different orders and mixtures to identify independent and overlapping epitopes.
Resonance unit (y axis) increases that exceeded the values found for IgG1 R11, R12, and Y31 alone indicated independent epitopes that allow
simultaneous binding. For example, the increase found for the combination of IgG1 R11 and R12 (top left and middle left graph) exceeded the values
found for R11 and R12 alone, indicating that R11 and R12 can bind simultaneously to human ROR1. By contrast, the increase found for the
combination of IgG1 Y31 and R11 (top right and bottom left graph) did not exceed the values found for R11 and Y31 alone, indicating overlapping
epitopes. The simultaneous binding of IgG1 R12 and Y31 can be seen in the middle right graph. The x axis depicts the time in seconds (s).
doi:10.1371/journal.pone.0021018.g004
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control), and chimeric mouse/human anti-CD20 IgG1 mAb
rituximab (positive control) followed by rabbit complement. Cell
death was quantified by propidium iodide (PI) staining using flow
cytometry. Whereas rituximab mediated potent CDC, none of the
other antibodies revealed cytotoxicity above background (Fig. 8),
and neither did a mixture of IgG1 R11 and R12 or rabbit anti-
human ROR1 IgG pAbs purified from the serum of our
immunized rabbits (data not shown). These findings suggested
that ROR1 is not a suitable antigen for mediating CDC by mAbs
or pAbs in IgG format regardless of epitope location.
ADCC assays with chimeric rabbit/human IgG1
With CDC ruled out as a potential mechanism of killing human
ROR1-expressing cells with our chimeric rabbit/human IgG1, we
next investigated ADCC. As before, we used JeKo-1 and HBL-2
cells in addition to PBMC prepared from CLL patients as target
cells. NK cells purified by negative magnetic selection from PBMC
of a healthy volunteer were used as effector cells. An effector-to-
target cell ratio of 25:1 was chosen despite the fact that in CLL and
leukemic MCL the number of circulating target cells is typically
much higher than the number of circulating effector cells (Fig. 7).
Using a bioluminescent intracellular protease detection assay, the
killing of JeKo-1 and HBL-2 cells by IgG1 R11, R12, and Y31 in
the presence of purified NK cells was quantified (Fig. 9A). IgG1
TT11 and rituximab were used as negative and positive control,
respectively. At the chosen concentration of 5 mg/mL, only
rituximab and IgG1 R12 mediated ADCC significantly above
background toward both MCL cell lines. The same trend,
although not significant, was found when PBMC from three
CLL patients (Fig. 7) with 80% or more CD19+ CD5+ ROR1+
cells were used as target cells (Fig. 9B). Mixtures of IgG1 R11 and
R12 did not reveal higher ADCC potency when compared to
IgG1 R12 alone (data not shown). To further study their ADCC
potency, we compared the same panel of mAbs over a
concentration range of 0.02 to 20 mg/mL using the same assay
with an effector-to-target cell ratio of 20:1 (Fig. 9C). HBL-2 cells
were used as target cells and purified NK cells from a different
healthy volunteer as effector cells. Consistent with the previous
experiments, IgG1 R12 was the only anti-ROR1 mAb that
mediated ADCC at high concentrations. Nonetheless, its ADCC
potency was vastly outdone by rituximab which demonstrated
stable cytotoxicity over the entire concentration range (Fig. 9C).
Although various protein and carbohydrate engineering strategies
for improving the ADCC potency of mAbs exist, our findings
argue against singling out ADCC as an effective strategy for killing
human ROR1-expressing cells.
Internalization of chimeric rabbit/human IgG1
We next investigated whether internalization or dissociation
could account for the inability of IgG1 R11, R12, and Y31 to
mediate effective CDC and ADCC. We had previously shown that
human ROR1 can mediate internalization of polyclonal goat anti-
human ROR1 IgG by a route that can be completely blocked by
endocytosis inhibitor phenylarsine oxide [20]. PBMC from three
CLL patients were incubated with biotinylated IgG1 R11, R12,
and Y31 on ice, washed, and either left on ice or incubated at
37uC for 15 min, 30 min, 1 h, or 2 h. Subsequent staining with
PE-streptavidin was used to detect biotinylated IgG1 that had
remained at the cell surface. An MFI reduction was noted for all
three IgG1 after 2 h (Fig. 10). MFI reduction can be explained by
internalization or dissociation or a combination of both. In case of
IgG1 R11 and R12, phenylarsine oxide completely blocked MFI
reduction, revealing internalization as the dominating factor. By
contrast, dissociation clearly contributed to the steady disappear-
ance of IgG1 Y31 from the cell surface (Fig. 10). Internalization
studies with JeKo-1 and HBL-2 cells gave very similar results (data
not shown). Notably, IgG1 R12 internalized more slowly than
IgG1 R11 with peaks at 20–25% after 2 h compared to 50–55%.
It is possible that this difference in cell surface retention accounts
for the different ADCC potencies of IgG1 R12 and R11.
Apoptosis assays with chimeric rabbit/human IgG1
The ability of IgG1 R11, R12, and Y31 to induce or inhibit
apoptosis in primary CLL cells from patients was studied in the
absence or presence of fetal bovine serum (FBS). FBS is known to
enhance spontaneous apoptosis of primary CLL cells ex vivo [33].
Using FBS-free medium, we first investigated the induction of
apoptosis in PBMC from three CLL patients (Fig. 7) with 80% or
more CD19+ CD5+ ROR1+ cells following incubation for three
days with IgG1 R11, R12, Y31, TT11, and rituximab alone or in
the presence of a cross-linking pAb. As shown in Fig. 11A, the only
increase in spontaneous apoptosis was noted for cross-linked
rituximab. This was consistent and reproducible for all three
PBMC samples tested. In the presence of FBS, apoptosis was
approaching 50% after three days as expected (Fig. 11B). As
observed previously [20], addition of IL-4 and CD40L strongly
suppressed apoptosis. IgG1 R11, R12, Y31, and TT11 (negative
control) neither increased nor decreased apoptosis alone or after
cross-linking. They also did not influence the suppression of
apoptosis by IL-4 and CD40L. By contrast, cross-linked rituximab
was found to increase apoptosis and partially override its
suppression (Fig. 11B). Collectively, this data demonstrates that
our panel of chimeric rabbit/human IgG1 does neither induce nor
inhibit apoptosis of primary CLL cells. We also investigated the
induction of apoptosis in MCL cell line HBL-2 (data not shown). In
contrast to primary CLL cells, rituximab alone was sufficient to
induce apoptosis in HBL-2 cells. This activity was further increased
after cross-linking. Nonetheless, IgG1 R11, R12, and Y31 did not
induce apoptosis in HBL-2 cells with or without cross-linking.
Table 2. Affinities and avidities of R11, R12, and Y31 in Fab
and IgG1 formats.
1
MAb Antigen
kon
(10
5)( M
21s
21)
koff
(10
24)( s
21)
Kd
(nM)
Fab R11 Fc-hROR1 20.4 54.7 2.7
Fc-mROR1 16.9 50.4 3.0
IgG1 R11 Fc-hROR1 19.4 3.6 ‘‘0.19’’
Fc-mROR1 9.9 3.0 ‘‘0.30’’
Fab R12 Fc-hROR1 5.5 3.1 0.56
Fc-mROR1 no binding no binding no binding
IgG1 R12 Fc-hROR1 5.5 0.62 ‘‘0.11’’
Fc-mROR1 no binding no binding no binding
Fab Y31 Fc-hROR1 8.5 75.2 8.8
Fc-mROR1 9.1 38.3 4.2
IgG1 Y31 Fc-hROR1 4.9 3.5 ‘‘0.71’’
Fc-mROR1 5.4 2.4 ‘‘0.44’’
1Fc-hROR1 or Fc-mROR1 were immobilized on the sensor chip. Association (kon)
and dissociation (koff) rate constants were calculated using Biacore 6100
evaluation software. The equilibrium dissociation constant (Kd), which is shown
in quotes for IgG1 to indicate the contribution of the avidity effect, was
calculated from koff/kon.
doi:10.1371/journal.pone.0021018.t002
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Based on its favorable expression profile, receptor tyrosine
kinase ROR1 is preclinically investigated as a new target for mAb
therapy of CLL and MCL. Here we describe a panel of mAbs in
chimeric rabbit/human Fab and IgG1 formats that were selected
by phage display. This panel bound to a diverse set of epitopes
covering all three domains in the extracellular region of human
ROR1. Whereas the IgG1 format of this panel demonstrated
comparable subnanomolar avidities for purified human ROR1,
the distinct epitopes appeared to dictate substantially dissimilar cell
surface binding and internalization characteristics. These distinc-
tive properties were consistent for all cells we tested, including
human MCL cell lines JeKo-1 and HBL-2 and primary CLL cells
from different patients with variable cell surface densities of
human ROR1.
Another distinctive property of the panel of selected mAbs to
human ROR1 was cross-reactivity with mouse ROR1. Whereas
R12 bound only human ROR1, R11 and Y31 recognized both
human and mouse ROR1. We had previously shown that the
selection of chimeric rabbit/human Fab libraries against con-
served human antigens often yields mAbs that cross-react with
their mouse and rat orthologs [25,26,27]. Human and mouse
ROR1 share 97% amino acid sequence identity in the
extracellular region. Notably, the Fz and Kr domains which
harbor the epitopes of the cross-reacting mAbs R11 and Y31 are
more conserved (99% amino acid sequence identity) than the Ig
Figure 5. Affinity measurements by surface plasmon resonance. Shown are Biacore6100 sensorgrams obtained for the binding of Fab and
IgG1 R11, R12, and Y31 to immobilized Fc-hROR1 (A) and Fc-mROR1 (B) after instantaneous background depletion. The mAbs were injected at five or
six different concentrations (shown in different colors) ranging from 1.5 to 100 nM. Each concentration was tested in duplicates.
doi:10.1371/journal.pone.0021018.g005
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sequence identity) which harbors the epitope of the non-cross-
reacting mAb R12. MAbs that recognize human and mouse
ROR1 equally well are better suited for safety and activity
assessments in xenogeneic and syngeneic mouse models and may
allow a faster transition from preclinical to clinical studies as there
is no need for developing surrogate mAbs. An analysis of publicly
available genomic DNA sequences of the nonhuman primates Pan
troglodytes and Macaca mulatta predicted that hROR1ECD shares
100% amino acid sequence identity with the corresponding
chimpanzee and macaque protein (data not shown). Thus, mAbs
and antibody derivatives that utilize the rabbit variable domains of
R11, R12, and Y31 are suitable for preclinical toxicology studies
in nonhuman primates.
The inability of our panel of chimeric rabbit/human IgG1 to
mediate effective CDC and ADCC is likely a consequence of the
relatively low cell surface density of ROR1. We previously
determined that primary CLL cells express cell surface ROR1 in
a range of 10
3 to 10
4 molecules per cell [20]. By comparison, our
flow cytometry data suggest that MCL cell lines JeKo-1 and HBL-
2 express roughly 1–2610
4 cell surface ROR1 molecules per cell.
This is still one to two orders of magnitude below the typical cell
surface density of antigens targeted by FDA-approved mAbs.
Other investigational antigens in B-cell malignancies with cell
surface densities comparable to ROR1, such as CD74 [34], were
also found to be incapable of mediating ADCC and CDC. Even
CD20, when expressed at relatively low cell surface densities of
typically less than 5610
4 molecules per cell in CLL [35], may not
mediate effective ADCC as suggested by the discovery that Fcc
receptor polymorphisms in CLL patients [36] do not influence the
outcome of FC versus FCR therapy [37]. A likely mechanism of
the clinical activity of rituximab in combination with chemother-
apy is chemosensitization [38]. Although our anti-ROR1 mAbs
did not induce apoptosis in primary CLL cells, they may still
enhance the apoptotic activity of chemotherapy. Thus, it was
important to demonstrate that our anti-ROR1 mAbs, unlike IL-4
and CD40L, do not provide detectable anti-apoptotic stimuli.
MAbs to certain tyrosine kinase receptors, such as c-Met [39,40],
can exhibit undesired agonistic activity by mimicking the ligand
and cross-linking the receptor.
Although our study suggests that naked mAbs to ROR1 may
have limited therapeutic utility, it will be important to conduct in
vivo studies as alternate mechanisms of activity, such as interference
with yet unknown receptor/ligand interactions, cannot be assessed
in vitro and ex vivo. In fact, the existence of endogenous anti-ROR1
antibodies that are triggered in CLL patients with clinical
responses to an autologous cell vaccine [21] or lenalidomide
[41] points to an alternate mechanism of activity. Relevant in vivo
studies that may help to evaluate the therapeutic utility of naked
anti-ROR1 mAbs will require mouse models that permit the
transfer and proliferation of primary CLL or MCL cells.
Nonetheless, we propose that ROR1 may be a preferred target
for armed rather than naked mAbs. We recently demonstrated
that ROR1-expressing primary cells and cell lines can be killed
with T cells that express a ROR1-specific chimeric antigen
receptor based on a mouse mAb to ROR1 [23]. It will be
Figure 6. Cell surface binding. Flow cytometry was used to analyze the binding of IgG1 R11 (green line; 5 mg/mL), R12 (blue line; 1 mg/mL), and
Y31 (red line; 5 mg/mL) to (A) the surface of JeKo-1 (top) and HBL-2 cells (bottom) and (B) PBMC from patient CLL-1. The gray shade indicates the
background observed with TT11 (A;5mg/mL) or P14 (B;5mg/mL). Biotinylated IgG1 alone (A) or in combination with FITC-CD19/APC-CD5 (B) were
detected with PE-streptavidin. The y axis depicts the number of events, the x axis the fluorescence intensity.
doi:10.1371/journal.pone.0021018.g006
Table 3. Flow cytometry binding of IgG1 R11, R12, Y31, and
control antibodies to PBMC from patient CLL-1.
0.01 mg/mL 0.1 mg/mL 1 mg/mL 5 mg/mL 10 mg/mL
IgG1 R11 ND
1 6.6
2 18.1 64.9 137.7
IgG1 R12 36.4 89.4 97.9 121.8 ND
IgG1 Y31 ND 5.4 8.3 21.6 58.9
IgG1 TT11 4.9 4.8 7.2 7.3 7.3
1Not determined.
2Mean Fluorescence Intensity (MFI).
doi:10.1371/journal.pone.0021018.t003
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and Y31 chimeric antigen receptors as they provide a range of
different affinities and epitopes. Our internalization data suggests
that ROR1 may also be a suitable target for the delivery of
cytotoxic payloads by antibody-drug conjugates and immunotox-
ins. It will be particularly interesting to compare the substantially
Figure 8. CDC. PI staining followed by flow cytometry was used to analyze the CDC potency of IgG1 R11, R12, and Y31 in comparison to IgG1 P14
(negative control), and rituximab (RTX; positive control; all at 10 mg/mL) toward JeKo-1 cells (left), HBL-2 cells (middle), and PBMC from patient CLL-6
(right) in the presence of rabbit complement. The percentage of dead cells (PI-positive) after RTX-mediated CDC was 70.7% (JeKo-1), 54.4% (HBL-2),
and 12.7% (CLL).
doi:10.1371/journal.pone.0021018.g008
Figure 7. Specificity of cell surface binding. Flow cytometry was used to identify PBMC subpopulations from patients CLL-2 (A), CLL-3 (B), CLL-4
(C), and CLL-5 (D) as NK cells (CD16+ CD32), T cells (CD162 CD3+ and CD192 CD5+), and CLL cells (CD19+ CD5+). The binding of biotinylated IgG1
R12 (blue; 1 mg/mL) to total PBMC is shown at the bottom. The gray shade indicates the background observed with PE-streptavidin alone. The x and y
axes in the top and middle row and the x axis in the bottom row depict the fluorescence intensity, the y axis in the bottom row the number of events.
doi:10.1371/journal.pone.0021018.g007
Targeting ROR1 with Monoclonal Antibodies
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21018dissimilar cell surface binding and internalization characteristics of
R11 and R12 with respect to effective delivery of cytotoxic
payloads.
In summary, we here describe a first generation of chimeric
rabbit/human Fab and IgG1 that bind ROR1 with high affinity
and specificity and provide both rationale and platform for a
second generation of mAbs and antibody derivatives.
Materials and Methods
Primary cells and cell lines
Untreated CLL patients were enrolled in an institutional review
board-approved observational study protocol at the Clinical
Center, National Institutes of Health (NIH; Bethesda, MD) [42].
Written informed consent was obtained from all study partici-
pants. PBMC were prepared from blood by density gradient
centrifugation using Lymphocyte Separation Medium (MP
Biomedicals; Solon, OH) and used freshly or cryopreserved in
liquid nitrogen until use. PBMC from healthy volunteers who gave
written informed consent were prepared from fresh apheresis
donations obtained from the Department of Transfusion Medi-
cine, Clinical Center, NIH. Human NK cells (CD16+ CD56+)
were negatively selected and purified from PBMC by magnetic
activated cell sorting using the NK Cell Isolation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany). Human MCL cell lines
JeKo-1 and HBL-2 were obtained from American Type Culture
Collection (Manassas, VA) and maintained in RPMI 1640
(Invitrogen; Carlsbad, CA) supplemented with 10% (v/v) heat-
inactivated FBS (Thermo Scientific; Logan, UT), 100 U/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen). HEK 293F
cells (Invitrogen) stably transfected with a mammalian expression
vector (OriGene, Rockville, MD) that contained the full-length
cDNA of human ROR1 (HEK 293F/hROR1) were described
previously [31].
Construction, expression, and purification of
recombinant ROR1 proteins
hROR1ECD. A cDNA fragment encoding a shortened
extracellular region of human ROR1 (amino acids 51–391 +
Figure 9. ADCC. A bioluminescent intracellular protease detection assay was used to quantify the ADCC potency of IgG1 R11, R12, and Y31 in
comparison to IgG1 TT11 (negative control) and rituximab (RTX; positive control; all at 5 mg/mL) toward (A) MCL lines JeKo-1 and HBL-2 and (B) PBMC
from patients CLL-2, CLL-3, and CLL-4. NK cells isolated from PBMC of a healthy volunteer were used as effector cells at an effector-to-target cell ratio
of 25:1. In (A), specific cytotoxicity is shown as columns with error bars to indicate mean and standard deviation values of side-by-side triplicates.
Stars indicate significant differences (p,0.05) to both the negative control (IgG1 TT11) and the background (none). In (B), specific cytotoxicity toward
PBMC from the three individual patients is shown with mean values indicated by horizontal bars. (C) Using the same assay and mAbs, ADCC potency
toward HBL-2 cells was compared over a concentration range of 0.02 to 20 mg/mL. NK cells isolated from PBMC of a different healthy volunteer were
used at an effector-to-target cell ratio of 20:1. Columns indicate mean values and error bars indicate standard deviation values of side-by-side
triplicates.
doi:10.1371/journal.pone.0021018.g009
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5-K-sROR1ECD (gggtaccatggactggacctggagaatcctcttcttggtggcag-
cagccacaggagctcactccgaactcaacaaagattcttacctgac) and 3-B-sROR-
1ECD (gaggaggagggatccttatttaccgcacgctgggatgtcacacagatcagac)
using ROR1 isoform 1 (GenBank accession no. NM_005012)
TrueClone cDNA (OriGene) as template and was subsequently
cloned via KpnI/BamHI into mammalian expression vector pCEP4
(Invitrogen). Note that the C-terminus of hROR1ECD is identical
to ROR1 isoform 2 (GenBank accession no. NM_001083592). Fc-
hROR1. A cDNA fragment encoding the entire extracellular
region of human ROR1 (amino acids 24–403) was custom
synthesized by GenScript (Piscataway, NJ) and cloned into pCEP4
via HindIII/BamHI (pCEP4-hROR1). A genomic exon/intron
sequence encoding human Fcc1, equipped with a VH leader
sequence, a modified hinge region, and a modified C-terminus
[43], was PCR-amplified with primers 5-K-FcX (gggtaccatggactg-
gacctggaggatcctcttcttggtggcagcagccacaggagctcactccgagcccaaatcttc-
tgacaaaactcacaca) and 3-H-FcX (cggagacaagcttaggctcttctgcgtg-
tagtggttgtgcag) and cloned into pCEP4-hROR1 via Kpn I/Hind
III. Fc-mROR1. A cDNA fragment encoding a shortened
extracellular region of mouse ROR1 (amino acids 51–391 +
GK; GenBank accession no. NM_013845) was custom synthesized
by DNA 2.0 (Menlo Park, CA) and cloned into pCEP4-Fc [43] via
HindIII/XhoI. Fc-hROR1ig. A cDNA fragment encoding the Ig
domain of human ROR1 (amino acids 51–147) was PCR-
amplified with primers 5-H-Fc-ROR1ig (gagaagcttgtctccgggtgcc-
gaactcaacaaagattcttacctgac) and 3-X-Fc-ROR1ig (gagctcgagt-
taaaacaagactccagtggaagaaacc) using ROR1 isoform 1 TrueClone
cDNA as template and was subsequently cloned via Hind III/Xho I
into pCEP4-Fc. Fc-hROR1fz. Analogous to Fc-hROR1ig, a
cDNA fragment encoding the Fz domain of human ROR1 (amino
acids 165–299) was cloned using primers 5-H-Fc-ROR1fz
(gagaagcttgtctccgggtgccgaagaagatggattctgtcagcca) and 3-X-Fc-
ROR1fz (gagctcgagttaaatccggatacagttcgcagcttc). Fc-hROR1kr.
Analogous to Fc-hROR1ig, a cDNA fragment encoding the Kr
domain of human ROR1 (amino acids 312–391 + GK) was cloned
using primers 5-H-Fc-ROR1ki (gagaagcttgtctccgggtgccaagtgtta-
taacagcacaggtgtgga) and 3-X-Fc-ROR1ki (gagctcgagttatttaccg-
cacgctgggatgtc). Fc-hROR1ig+fz. Analogous to Fc-hROR1ig, a
cDNA fragment encoding both Ig and Fz domain of human
ROR1 (amino acids 51–299) was cloned using primers 5-H-Fc-
ROR1ig and 3-X-Fc-ROR1fz. Fc-hROR1fz+kr. Analogous to
Fc-hROR1ig, a cDNA fragment encoding both Fz and Kr domain
of human ROR1 (amino acids 165–391 + GK) was cloned using
primers 5-H-Fc-ROR1fz and 3-X-Fc-ROR1kr. All eight con-
structs were transiently transfected into HEK 293F cells (Invitro-
gen) using 293fectin (Invitrogen) and conditions detailed in the
manufacturer’s protocol. Transfected cells were cultured in
FreeStyle protein-free medium (Invitrogen) and the seven Fc
fusion proteins of ROR1 were purified from supernatants by
Protein A affinity chromatography as described [27]. In case of
hROR1ECD, the supernatant was filtered through a 0.45-mm
membrane and tenfold concentrated using an ultrafiltration device
with a 10-kDa cutoff membrane (Millipore; Billerica, MA) and
brought into buffer A (20 mM sodium phosphate, 25 mM NaCl,
pH 7.4) using the same device. The concentrated sample was then
purified by ion exchange chromatography using a 1-mL HiTrap
Q FF column (GE Healthcare) and a 0–100% gradient to buffer B
(20 mM sodium phosphate, 500 mM NaCl, pH 7.4). The eluted
sample was brought into PBS using a 10-kDa cutoff centrifugal
filter device (Millipore) and further purified by gel filtration
chromatography using a Superdex 200 10/300 GL column (GE
Healthcare). All chromatography procedures were carried out
with an A ¨KTA FPLC instrument (GE Healthcare). The quality
and quantity of purified recombinant ROR1 proteins was
analyzed by SDS-PAGE and absorbance at 280 nm, respectively.
Generation and selection of chimeric rabbit/human Fab
libraries
All rabbit handling was carried out by veterinary personnel at
Spring Valley Laboratories, Inc. (Woodbine, MD). A total of six
b9 allotype rabbits were used. Four rabbits were immunized and
boosted three times with 100 mg Fc-hROR1, using Freund’s
complete and incomplete adjuvant (Sigma-Aldrich; St. Louis, MO)
for two rabbits and TiterMax adjuvant (Sigma-Aldrich) for the
other two rabbits. Library R was based on these four rabbits.
Library Y was based on two additional rabbits that were
immunized with 100 mg Fc-hROR1 and boosted three times with
100 mg hRORECD using Ribi (Sigma-Aldrich) adjuvant. Spleen
and bone marrow from both femurs of each rabbit were collected
five days after the final boost and processed for total RNA
preparation and RT-PCR amplification of rabbit Vk,V l, and VH
encoding sequences using established primer combinations and
protocols [28]. Rabbit VL/human Ck/rabbit VH segments were
assembled in one fusion step based on 3-fragment overlap
Figure 10. Internalization. Shown is the internalization of IgG1 R11,
R12, and Y31 by PBMC from patients CLL-6 (top), CLL-7 (middle), and
CLL-8 (bottom). Biotinylated IgG1 R11 (10 mg/mL), R12 (1 mg/mL), and
Y31 (10 mg/mL) were incubated at 37uC and analyzed at the indicated
time points with PE-streptavidin. The percentage of MFI reduction was
calculated as described in Materials and Methods. The data set on the
right shows MFI reduction in the presence of endocytosis inhibitor
phenylarsine oxide (PAO).
doi:10.1371/journal.pone.0021018.g010
Targeting ROR1 with Monoclonal Antibodies
PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e21018extension PCR, digested with SfiI, and cloned into pC3C as
described [28]. Transformation of E. coli strain XL1-Blue
(Stratagene; La Jolla, CA) by electroporation yielded approxi-
mately 2.5610
8 and 1.4610
8 independent transformants for
library R and Y, respectively. Using VCSM13 helper phage
(Stratagene), the phagemid libraries were converted to phage
libraries and selected by panning against immobilized protein as
described [28]. Library R and Y were selected in parallel by four
rounds of panning against hROR1ECD. Library Y was also
selected by three rounds of panning on hROR1ECD followed by a
final panning round on Fc-hROR1. During the panning against
immobilized Fc-hROR1, unspecific polyclonal human IgG
(Thermo Scientific; Rockford, IL) were added as decoy at a final
concentration of 1 mg/mL. Supernatants of IPTG-induced selected
clones were analyzed by ELISA using immobilized hROR1ECD
and Fc-hROR1 and by flow cytometry using HEK 293F cells
stably transfected with human ROR1 [31]. A C-terminal
hemagglutinin (HA) decapeptide tag encoded on pC3C was used
for detection as described below. Repeated clones were identified
by DNA fingerprinting with AluI, and the VL and VH sequences of
unique clones were determined by DNA sequencing as described
[28].
Expression and purification of chimeric rabbit/human
Fab
To remove HA tag and gene III fragment encoding sequences
of pC3C [27] and add a C-terminal (His)6 tag, the expression
cassettes encoding Fab R11, R12, and Y31 were transferred by SfiI
cloning into a Fab-(His)6 expression cassette in vector pET11a
with an IPTG-inducible T7 promoter [44]. Following transfor-
mation into E. coli strain BL21-CodonPlus(DE3)-RIL (Stratagene)
and expression through IPTG induction, Fab R11, R12, and Y31
were purified from bacterial supernatants by Immobilized Metal
Ion Affinity Chromatography using a 1-mL HisTrap column (GE
Healthcare) as described [45] followed by gel filtration chroma-
tography using a Superdex 200 10/300 GL column with an
A ¨KTA FPLC instrument (GE Healthcare). The quality and
quantity of purified Fab was analyzed by SDS-PAGE and
absorbance at 280 nm, respectively.
Expression, purification, and biotinylation of chimeric
rabbit/human IgG
For the expression of R11, R12, and Y31 in IgG1 format, the
previously described vector PIGG was used [25]. In this vector, c1
heavy and k light chain are expressed by an engineered
bidirectional CMV promoter cassette. The VH encoding sequenc-
es of Fab R11 and R12 were PCR amplified using primers R11-
VH-59(gaggaggagctcactcccagtcggtgaaggagtccga) and P14-VH-
59[27], respectively, in combination with R11-12-VH-
39(ccgatgggcccttggtggaggctgaggagatggtgaccagggtgcctggtccccagatg),
and cloned via ApaI/SacI into PIGG. The light chain encoding
sequences of Fab R11 and R12 were PCR amplified using primers
P14-light-59 [27] and R12-light-59(gaggagaagcttgttgctctg-
gatctctggtgcctacggggaactcgtgctgactcagtc), respectively, in combi-
nation with primer C-kappa-39 [27], and cloned via HindIII/XbaI
into PIGG with the corresponding heavy chain encoding
sequence. Note that the resulting chimeric rabbit/human light
chain of R12 is composed of a rabbit Vl and a human Ck domain.
Figure 11. Apoptosis. PBMC from patients CLL-2 (black), CLL-3 (gray), and CLL-4 (white) cultured without (A) and with (B) FBS, were incubated with
IgG1 R11, R12, Y31, TT11, and rituximab (RTX) for 72 h in the absence (2) and presence (+) of F(ab9)2 goat anti-human IgG (cross-linker). IL-4 and
CD40L were added (+)i n( B) to suppress apoptosis in the presence of FBS. Cytotoxicity was measured by separating live from apoptotic and dead
cells by flow cytometry using Alexa Fluor 647 Annexin V and SYTOX Green nucleic acid stain.
doi:10.1371/journal.pone.0021018.g011
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primers M5-VH-59 and M5-VH-39 [27], and cloned via ApaI/
SacI-ligation into PIGG. To remove an internal HindIII site by
silent mutation, two fragments of the light chain encoding
sequence of Fab Y31 were PCR amplified using primers P14-
light-59 in combination with Y31-light-39(attggatgcataatagatcag-
tagcttgggaggctg) and Y31-light-59(aaccagggcagcctcccaagctactgatct)
in combination with C-kappa-39, fused by overlap extension PCR
using primers P14-light-59 and C-kappa-39, and cloned via
HindIII/XbaI into PIGG with the corresponding heavy chain
encoding sequence. The resulting PIGG-R11, PIGG-R12, and
PIGG-Y31 plasmids were transiently transfected into HEK 293F
cells (Invitrogen) using 293fectin (Invitrogen), and purified with a
1-mL recombinant Protein A HiTrap column (GE Healthcare,
Piscataway, NJ) as described [27]. The quality and quantity of
purified IgG1 was analyzed by SDS-PAGE and A280 absorbance,
respectively. Chimeric rabbit/human IgG1 P14, which recognizes
the LRRCT-unique fragment of human, rat, and mouse Nogo-66
receptor family member NgR2 [27], was expressed and purified as
described previously [27] and used as negative control. Purified
chimeric rabbit/human IgG1 was biotinylated using the Biotin-
Tag Micro Biotinylation kit (Sigma-Aldrich). Briefly, 200 mg IgG1
in 50 mL of 0.1 M sodium phosphate buffer (pH 7.2) was
incubated with 2 mL of 5 mg/mL biotinamidohexanoic acid 3-
sulfo-N-hydroxysuccinide ester for 30 min at room temperature
with gentle stirring. Biotinylated IgG1 was isolated using
MicroSpin G-50 Columns provided by the kit.
ELISA
For coating, each well of a 96-well Costar 3690 plate (Corning;
Corning, NY) was incubated with 100 ng antigen in 25 mL TBS
for 1 h at 37uC. After blocking with 150 mL 3% (w/v) BSA/TBS
for 1 h at 37uC, 50 mL 500 ng/mL purified IgG1 (25 ng/well) in
1% (w/v) BSA/TBS was added, incubated for 2 h at 37uC,
washed with H2O (106200 mL/well), and incubated with 50 mLo f
a 1:1,000 dilution of goat anti-human kappa pAbs conjugated to
horseradish peroxidase (HRP) (Southern Biotech; Birmingham,
AL) in 1% (w/v) BSA/TBS for 1 h at 37uC. Washing with H2O
was repeated and colorimetric detection was performed using 2,29-
azino-bis(3-ethylbenzthiazoline)-6-sulfonic acid (Roche; Indianap-
olis, IN) as substrate according to the manufacturer’s directions. In
the same ELISA, 50 mL 500 ng/mL goat anti-human ROR2
pAbs (R&D Systems, Minneapolis, MN) followed by 50 mLo fa
1:1,000 dilution of donkey anti-goat IgG (H+L) pAbs conjugated
to HRP (Jackson ImmunoResearch; West Grove, PA) were used as
control. For the ELISA with bacterial supernatants after library
selection, rat anti-HA mAb 3F10 conjugated to HRP (Roche) was
used at a concentration of 50 ng/mL. The absorbance was
measured at 405 nm using a VersaMax microplate reader
(Molecular Devices; Sunnyvale, CA) and SoftMax Pro software
(Molecular Devices).
Surface plasmon resonance
Surface plasmon resonance for the measurement of the affinities
of Fab R11, R12, and Y31 and the virtual affinities of IgG1 R11,
R12, and Y31 to Fc-hROR1 and Fc-mROR1 as well as for
epitope mapping studies were performed on a Biacore 6100
instrument using Biacore reagents and software (GE Healthcare).
For affinity measurements, CM5 sensor chips were activated for
immobilization with 1-ethyl-3-(3-dimethylaminopropyl)carbodii-
mide hydrochloride and N-hydroxysuccinimide. Fc-hROR1 and
Fc-mROR1 fusion proteins in 10 mM sodium acetate (pH 5.0)
were immobilized at a density of 669 resonance units (RU) for Fc-
hROR1 and 429 RU for Fc-mROR1 in two flow cells on separate
sensor chips. Subsequently, the sensor chips were deactivated with
1 M ethanolamine hydrochloride (pH 8.5). Each sensor chip
included an empty flow cell for instantaneous background
depletion. All binding assays used 16 HBS-EP+ running buffer
(10 mM HEPES, 150 mM NaCl, 3 mM EDTA (pH 7.4), and
0.05% (v/v) Surfactant P20) and a flow rate of 30 mL/min. Fab
and IgG1 R11, R12, and Y31 were injected at five or six different
concentrations ranging from 1.5 to 100 nM in duplicates. The
sensor chips were regenerated with glycine-HCl (pH 2.0) without
any loss of binding capacity. Calculation of association (kon) and
dissociation (koff) rate constants was based on a 1:1 Langmuir
binding model. The equilibrium dissociation constant (Kd) was
calculated from koff/kon. For epitope mapping studies, Fc-hROR1
was immobilized on a CM5 sensor chip at a density of 219 RU.
IgG1 R11, R12, and Y31 were prepared as 300 nM solution in 16
HBS-EP+ running buffer. In the first cycle, IgG1 R11 was injected
first, followed by a mixture of IgG1 R11 and R12, followed finally
by a mixture of IgG1 R11, R12, and Y31. IgG1 R11 or IgG1 R11
in combination with IgG1 R12 were included in these mixtures to
prevent signal loss due to dissociation. In the second cycle the
injection order was R11, R11+Y31, and R11+Y31+R12. Analo-
gously, R12 was injected first in the third and fourth cycle, and
Y31 was injected first in the fifth and sixth cycle. RU increases that
exceeded the values found for IgG1 R11, R12, and Y31 alone
indicated independent epitopes that allow simultaneous binding.
Flow cytometry
Cells were stained using standard flow cytometry methodology.
Briefly, for anti-ROR1 Fab, cells were stained with unpurified or
purified (5 mg/mL) Fab on ice for 1 h. After washing twice with
ice-cold flow cytometry buffer (PBS containing 1% (v/v) FBS),
cells were incubated with 5 mg/mL of biotinylated rat anti-HA
mAb 3F10 (Roche) in flow cytometry buffer on ice for 1 h, washed
as before, and stained with 2 mg/mL PE-streptavidin (BD
Biosciences) on ice for 30 min. For anti-ROR1 IgG1, cells were
first blocked with 100 mg/mL unspecific polyclonal human IgG at
room temperature for 20 min, then incubated on ice for 1 h with
different concentrations (0.01–10 mg/mL) biotinylated anti-ROR1
IgG1 alone (for HEK 293F/hROR1, JeKo-1, and HBL-2 cells) or
in combination with FITC-CD19/APC-CD5 and FITC-CD3/
APC-CD16 (BD Biosciences; Franklin Lakes, NJ) (for PBMC from
CLL patients). After washing twice with ice-cold flow cytometry
buffer, cells were stained with 2 mg/mL PE-streptavidin on ice for
30 min. PI was added to a final concentration of 5 mg/mL to
exclude dead cells from analysis. Cells were analyzed using a
FACSCalibur instrument (BD Biosciences) and FlowJo analytical
software (Tree Star, Ashland, OR).
CDC
JeKo-1 and HBL-2 cells or cryopreserved PBMC from CLL
patients were harvested, washed, and resuspended in RPMI 1640
containing 10% (v/v) FBS, 100 U/mL penicillin, and 100 mg/mL
streptomycin, and distributed into 96-well U-bottom plates
(Corning) at a density of 1610
5 cells/well. After incubation for
1 h on ice with 10 mg/mL IgG1 R11, R12, Y31, negative control
P14, or positive control rituximab (Genentech; South San
Francisco, CA), the cells were harvested, washed once with PBS
to remove unbound antibodies, and incubated with 20%
complement from 3–4-week-old rabbits (Pel-Freez; Rogers, AR)
for 2 h at 37uCi n5 %C O 2. After adding PI to a final
concentration of 5 mg/mL, dead cells were detected by PI
accumulation using a FACSCalibur instrument and FlowJo
analytical software.
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ADCC was assayed in a bioluminescent protease release assay
(Glo Cytotoxicity Assay; Promega, Madison, WI) using the
manufacturer’s protocolwithminor modifications. NK cellsisolated
from PBMC of healthy volunteers by magnetic activated cell sorting
(as described before) were used as effector cells. JeKo-1 and HBL-2
cells orcryopreserved PBMC fromCLLpatients were used astarget
cells and distributed into 96-well U-bottom plates at a density of
1610
4 cells/well. The targetcellswerepreincubatedfor1 h at37uC
with serially diluted (from 20 to 0.02 mg/mL) IgG1 R11, R12, Y31,
TT11 (negative control), or rituximab (positive control). Without
washing, effector cells were added (100 mL/well) at an effector-to-
target cell ratio of 20:1 or 25:1 and incubated for 24 h at 37uCi n
5% CO2. After centrifugation, 50 mL/well of supernatant was
transferred to a 96-well white clear-bottom Costar 3610 plate
(Corning) followed by addition of 25 mL/well CytoTox-Glo
cytotoxicity assay reagent (Promega, Madison, WI). After 15 min
at room temperature, luminescence was measured with a Spectra
Max M5 microplate reader (Molecular Devices, Sunnyvale, CA).
The percentage of specific cytotoxicity was calculated according to
the formula: Percent specific cytotoxicity=1006(EX2Espon2
Tspon)/(Tmax2Tspon), where EX represents the release from
experimental wells, Espon is the spontaneous release of effector cells
alone,Tspon isthe spontaneousreleaseoftargetcellsalone,andTmax
is the maximum release from target cells lysed in 30 mg/mL
digitonin. Data was computed as mean 6 standard deviation of
triplicates. Probabilities (p) were determined with Prism 5 software
(GraphPad Software, La Jolla, CA) using the one-way ANOVA-
Bonferroni’s multiple comparison test; p,0.05 was considered
significant.
Internalization
Using a 96-well U-bottom plate, 3610
6 cryopreserved PBMC
from CLL patients were first blocked with 100 mg/mL unspecific
polyclonal human IgG at room temperature for 20 min, then
stained with 10 mg/mL biotinylated IgG1 R11 and Y31, or 1 mg/
mL biotinylated IgG1 R12 on ice for 1 h. Different concentrations
were chosen to achieve similar levels of cell surface binding. After
washing three times with flow cytometry buffer to remove
unbound antibody, the cells were either left on ice or incubated
at 37uC for 15 min, 30 min, 1 h, or 2 h to facilitate internaliza-
tion. For the 2-h time point, duplicate samples were incubated in
the absence or presence of 10 mM phenylarsine oxide (Sigma-
Aldrich). Subsequently, the cells were washed once with flow
cytometry buffer and incubated with PE-streptavidin on ice for
30 min. After three final washes with flow cytometry buffer, the
MFI of the cells was measured using a FACSCalibur instrument
and FlowJo analytical software. The percentage of MFI reduction
was calculated for each mAb relative to the unspecific polyclonal
human IgG control (MFIbackground) and mAb maintained on ice
(MFImax) by using the formula [(MFImax2MFIbackground)2
(MFIexperimental2MFIbackground)]/(MFImax2MFIbackground)6100.
Apoptosis
PBMC from CLL patients were distributed into 48-well flat-
bottom plates at a density of 5610
5 cells/well in either (i) serum-
free AIM-V medium (Invitrogen) supplemented with 50 mM b-
mercaptoethanol (Sigma-Aldrich) or (ii) RPMI 1640 supplemented
with 10% (v/v) heat-inactivated FBS, 100 U/mL penicillin, and
100 mg/mL streptomycin in the presence or absence of 100 ng/
mL recombinant human IL-4 (R&D Systems) and 1 mg/mL
soluble recombinant human CD40L trimer (Amgen, Thousand
Oaks, CA). Cells were incubated with 5 mg/mL IgG1 R11, R12,
Y31, TT11, or rituximab at 37uC in 5% CO2. For cross-linking,
20 mg/mL F(ab9)2 goat anti-human IgG (Fc-specific, Jackson
ImmunoResearch Laboratories) was added to the cell suspension
simultaneously with primary antibodies. Apoptosis and cell death
was measured by flow cytometry following staining with Alexa
Fluor 647 Annexin V (Invitrogen) and SYTOX Green nucleic
acid stain (Invitrogen). Briefly, cells were gently harvested after 72-
h incubation with indicated treatments, washed once with cold
apoptosis binding buffer (140 mM NaCl, 2.5 mM CaCl2,1 0m M
HEPES, pH 7.4), and resuspended in 200 mL apoptosis binding
buffer. After adding 1 mL Alexa Fluor 647 Annexin V and 1 mL
SYTOX Green to a final concentration of 50 nM, the cells were
incubated for 15 min in the dark at room temperature,
resuspended in 400 mL apoptosis binding buffer, and analyzed
using a FACSCalibur instrument and FlowJo analytical software.
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